Article
T2-high asthma phenotypes across lifespan.
The European respiratory journal - 1 Sept 2022
Maison Nicole, Omony Jimmy, Illi Sabina, Thiele Dominik, Skevaki Chrysanthi, Dittrich Anna-Maria, Bahmer Thomas, Rabe Klaus Friedrich, Weckmann Markus, Happle Christine, Schaub Bianca, Meyer Meike, Foth Svenja, Rietschel Ernst, Renz Harald, Hansen Gesine, Kopp Matthias Volkmar, von Mutius Erika, Grychtol Ruth, Fuchs Oliver, Roesler Barbara, Welchering Nils, Kohistani-Greif Naschla, Kurz Johanna, Landgraf-Rauf Katja, Laubhahn Kristina, Liebl Claudia, Ege Markus, Hose Alexander, Zeitlmann Esther, Berbig Mira, Marzi Carola, Schauberger Christina, Zissler Ulrich, Schmidt-Weber Carsten, Ricklefs Isabell, Diekmann Gesa, Liboschik Lena, Voigt Gesche, Sultansei Laila, Nissen Gyde, König Inke R, Kirsten Anne-Marie, Pedersen Frauke, Watz Henrik, Waschki Benjamin, Herzmann Christian, Abdo Mustafa, Biller Heike, Gaede Karoline I, Bovermann Xenia, Steinmetz Alena, Husstedt Berrit Liselotte, Nitsche Catharina, Veith Vera, Szewczyk Marlen, Brinkmann Folke, Malik Aydin, Schwerk Nicolaus, Dopfer Christian, Price Mareike, Jirmo Adan Chari, Habener Anika, DeLuca David S, Gaedcke Svenja, Liu Bin, Calveron Mifflin-Rae, Weber Stefanie, Schildberg Tom, van Koningsbruggen-Rietschel Silke, Alcazar Miguel
Abstract excerpt
RATIONALE: In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. OBJECTIVES: To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages. METHODS: In the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776...
Topics
Join the communities discussing this publication.